Agreed! I wasn’t sure how the rights offering would pan out. Now I know. Cytosorbents bought themselves another year of cash flow which should be enough time for the FDA “nod”. I’m optimistic that they will get the approval, and that analyst Jason Kolbert $10 price target is attainable. 🙂 Getting a little nostalgic but maybe even getting back into the lower teens like 2019. Have a great investing day!!
Market Data 
Markets 
AI
